Cipla recently announced the launch of its innovative inhaler, Synchrobreathe. This breath-actuated inhaler (BAI) is indicated for the millions of South Africans with obstructive airway diseases (OAD) such as asthma.
Paul Miller, CEO of Cipla Medpro, the third-largest pharmaceutical manufacturer in SA, says that Synchrobreathe will be welcomed by both patients and physicians, because of its key benefits in the treatment of OAD. “Incorrect use of inhalers and non-adherence to treatment are major contributors to the poor levels of asthma control we experience in SA.”
He points to the 2014 Global Asthma Report, released by the Global Asthma Network, which indicates that SA has the highest age-adjusted asthma death rate per million population. It is estimated that about 300 people in every million South Africans died from asthma every year from 2001-2010.
Synchrobreathe automatically delivers a dose of medicine as a mist when the patient inhales. The device is simple to use and eliminates coordination challenges, which is a major issue among South African patients who use inhalers, says Miller.
“In addition, the inspiratory flow required to automatically trigger the inhaler mechanism is low, which makes it attractive to a large number of patients, such as very young or old patients with severe lung impairment.
“Synchrobreathe is a breath-actuated inhaler with a true built-in dose counter allowing patients to track doses, thereby encouraging patient compliance.”
It is the first pMDI breath-actuated inhaler (BAI) with dose counter that contains fluticasone propionate and salmeterol xinafoate. The three simple steps make it easy to teach, learn and remember.
“Cipla’s Research and Development team, which specialises in respiratory inhalers, has been developing the product over several years. The launch and availability of the Synchrobreathe inhaler is in line with the company’s commitment to bring innovative solutions to best fit the needs of both physicians and patients, thereby advancing healthcare for all,” he said.